The most probable diagnosis in this case is hereditary spherocytosis. This conclusion is based on the patient’s presentation of jaundice, fatigue, and abdominal pain, along with a history of chronic fatigue and previous episodes of hepatitis. The absence of fever and travel history to endemic areas makes acute hepatitis and cholecystitis less likely.

The blood results showing low hemoglobin levels, high MCV, high reticulocyte count, and elevated LDH also point towards a chronic hemolytic anemia. The negative Coombs test rules out autoimmune hemolytic anemia, leaving hereditary spherocytosis as the most likely cause.

Hereditary spherocytosis is a genetic disorder that causes red blood cells to be more fragile, leading to their destruction and resulting in anemia. Splenomegaly and gallstones are common complications of this condition due to increased red cell destruction and hemoglobin metabolism. Abdominal ultrasound showing an enlarged spleen further supports the diagnosis of hereditary spherocytosis.

When considering switching an adolescent from a PI-containing regimen to a DTG-containing regimen, the factor taken into account based on the 2023 ART Clinical Guidelines is the viral load results in the last 12 months. This is because viral load results provide important information about the effectiveness of the current regimen in suppressing the HIV virus. If the viral load has been consistently undetectable or low, it may indicate that the current regimen is working well and there may not be a need to switch to a new regimen. However, if the viral load is high or increasing, it may suggest that the current regimen is not as effective and a switch to a new regimen, such as one containing DTG, may be necessary to better control the virus and prevent further progression of HIV.

Other factors that may also be considered when switching regimens include the adolescent’s weight, the presence of any specific drug allergies, time since the last opportunistic infection, and the adolescent’s preference for tablet size. However, viral load results are a key factor in determining the need for a regimen switch, especially for clients who have been on PI-based regimens for an extended period of time. By monitoring viral load results and making informed decisions based on this information, healthcare providers can ensure that adolescents are receiving the most effective and appropriate treatment for their HIV infection.

Herpes zoster, also known as shingles, is caused by the reactivation of the varicella zoster virus, which initially causes chickenpox. When the virus reactivates, it can cause painful vesicular lesions in a specific dermatome area, such as the ear canal in this case. The high-grade fever may be present due to the infection.

Varicella zoster is the virus responsible for chickenpox, not shingles. Measles is caused by the measles virus and presents with a characteristic rash, but not tender lesions in a specific area. Herpes simplex virus can cause cold sores or genital herpes, but not the specific presentation described in the question. HIV is a virus that attacks the immune system and can lead to various opportunistic infections, but it does not typically present with tender lesions in a specific area like herpes zoster.

Sensorineural deafness is strongly associated with rubella because primary rubella infection during pregnancy, particularly during the first trimester, can lead to congenital rubella syndrome (CRS). CRS can cause birth defects such as hearing impairment, eye defects, and cardiac defects. Congenital hearing loss is the most common sequela of CRS, occurring in approximately 60% of cases, especially when the infection occurs in the 4th month of pregnancy. Therefore, rubella is strongly associated with sensorineural deafness.

Drug-induced hepatitis is a condition where the liver becomes inflamed due to the toxic effects of certain medications. In this case, the question is asking which of the listed drugs is not a known cause of drug-induced hepatitis.

Ethambutol is not a cause of drug-induced hepatitis. It is primarily used in the treatment of tuberculosis and is known to cause ocular toxicity, specifically optic neuritis. This side effect is well-documented and occurs more commonly than liver toxicity.

Amiodarone, isoniazid, methyldopa, and pyrazinamide are all known to potentially cause drug-induced hepatitis. Amiodarone is an antiarrhythmic medication that can cause liver damage, isoniazid is used to treat tuberculosis and can lead to hepatitis, methyldopa is an antihypertensive medication that can cause liver inflammation, and pyrazinamide is another medication used in the treatment of tuberculosis that can also cause hepatitis.

Antenatal care is essential for ensuring the health and well-being of both the mother and the unborn child during pregnancy. The primary objectives of antenatal care typically include identifying and managing various health conditions that can affect the pregnancy and the health of the mother and baby.

In the options provided, identifying HIV infection and achieving viral suppression, identifying and treating syphilis and other infections, preventing transmission of hepatitis B virus (HBV) and other infections, and providing routine antenatal care according to guidelines are all primary objectives of antenatal care. These objectives focus on preventing and managing infectious diseases that can impact the health of the mother and baby during pregnancy.

However, screening for tuberculosis and other opportunistic infections is not typically considered a primary objective of antenatal care. While it is important to screen for and manage these infections, they are not directly related to the health of the mother and baby during pregnancy. Antenatal care primarily focuses on ensuring a healthy pregnancy and addressing any potential risks or complications that may arise.

Cryptococcal meningitis is a serious fungal infection that affects the brain and spinal cord, particularly in individuals with weakened immune systems such as those living with HIV. The recommended treatment for cryptococcal meningitis in this population is combination therapy with amphotericin B and fluconazole.

Amphotericin B is a potent antifungal medication that is effective in treating cryptococcal meningitis. It is typically administered intravenously to achieve high levels in the cerebrospinal fluid where the infection is located. However, amphotericin B can have significant side effects, including kidney toxicity, which is why it is often used in combination with another antifungal medication.

Fluconazole is an oral antifungal medication that is also effective in treating cryptococcal meningitis. When used in combination with amphotericin B, fluconazole helps to enhance the effectiveness of the treatment and reduce the risk of relapse. This combination therapy has been shown to improve outcomes and reduce mortality rates in patients with cryptococcal meningitis.

Overall, combination therapy with amphotericin B and fluconazole is the recommended treatment for cryptococcal meningitis in adults, adolescents, and children living with HIV who test positive for cryptococcal antigen (CrAg) in cerebrospinal fluid (CSF). It is important for healthcare providers to closely monitor patients receiving this treatment to ensure optimal outcomes and manage any potential side effects.

Squamous cell carcinoma of the cervix is often caused by the human papillomavirus (HPV), particularly strains 16 and 18. HPV infects the host and interferes with genes that regulate cell growth, leading to uncontrolled growth and inhibition of apoptosis. This results in precancerous lesions that can progress to carcinoma. Risk factors for cervical carcinoma include smoking, low socioeconomic status, use of the contraceptive pill, early sexual activity, co-infection with HIV, and a family history of cervical carcinoma. HIV is not the cause of cervical squamous cell carcinoma, but co-infection with HIV increases the risk of HPV infection. Epstein-Barr virus (EBV) is associated with other types of cancer, but not cervical squamous cell carcinoma. Chlamydia trachomatis is a bacterium associated with genitourinary infections, while herpes simplex virus (HSV) causes painful ulceration of the genital tract but is not associated with cervical carcinoma.

The weight-related eligibility criteria for TDF (Tenofovir Disoproxil Fumarate) were decreased from 35 kg to 30 kg according to the 2023 guidelines. This change was made to make TDF more accessible to a wider group of patients initiating antiretroviral therapy (ART). By lowering the weight requirement, more individuals who may benefit from TDF treatment will now be eligible to receive it. This change reflects a commitment to improving access to essential medications for all individuals living with HIV/AIDS, regardless of their weight.

In patients suspected of having acute hepatitis B infection, the earliest indicator of acute infection is the presence of Hepatitis B surface Antigen (HBsAg) in the serum. HBsAg appears in the serum within 1 to 10 weeks after acute exposure to HBV. This marker is considered the serological hallmark of HBV infection and its persistence for more than 6 months indicates chronic HBV infection.

The other markers mentioned in the question are not considered the earliest indicators of acute infection. Total hepatitis B core antibody (anti-HBc) is an intracellular presence in infected hepatocytes and is not identified in the serum. Hepatitis B surface antibody (anti-HBs) is a neutralizing antibody that confers long-term immunity, typically seen in patients with acquired immunity through vaccination. IgM antibody to hepatitis B core antigen (IgM anti-HBc) emerges 1-2 weeks after the presence of HBsAg during acute infection, but wears off after 6 months. Hepatitis delta virus serology refers to the presence of the delta hepatitis virus, a defective virus that requires HBV for replication and can occur in co-infection or superinfection with HBV.

Therefore, in the context of acute hepatitis B infection, the presence of HBsAg is the earliest and most important marker to consider.

Toxoplasmosis is a parasitic infection caused by the Toxoplasma gondii parasite. It can be transmitted through ingestion of contaminated food or water, handling cat litter, or from mother to fetus during pregnancy.

The correct statement regarding toxoplasmosis is that it can present with fits in patients with AIDS. This is because individuals with weakened immune systems, such as those with AIDS, are more susceptible to developing symptoms of toxoplasmosis, including seizures or fits.

Infection in the first trimester of pregnancy is actually very harmful to the fetus, as it can lead to serious complications such as intracranial calcifications, hydrocephalus, and blindness. Prophylactic immunoglobulins should be given to pregnant women if their IgM anti-toxoplasma antibodies are detected to help prevent transmission to the fetus.

Toxoplasmosis is usually acquired through ingestion of contaminated food or water, not through respiration. Raw eggs are not a common source of infection for toxoplasmosis, as it is typically associated with cat feces or raw/undercooked meat.

Overall, toxoplasmosis can have serious consequences, especially for pregnant women and individuals with weakened immune systems. It is important to take precautions to prevent infection and seek medical treatment if symptoms develop.

The most effective course of treatment for a patient who is HIV positive and experiencing depression would be to prescribe Citalopram. Citalopram is the preferred first-line treatment for depression in patients with HIV because it has minimal impact on the cytochrome system and does not interfere with HIV medications. This is important because some antidepressants, like fluoxetine, can interact with HIV medications and cause complications.

Other medications like TCAs (Amitriptyline, Lofepramine) are generally not well-tolerated in HIV patients due to severe side effects. MAOIs are also not recommended. While other medications such as mirtazapine, trazodone, reboxetine, and bupropion have been studied, they were limited by high rates of side effects.

It is important to address mental health issues in patients with HIV as depression is common in this population and can have a significant impact on their quality of life. By prescribing the appropriate medication, like Citalopram, healthcare providers can help improve the mental health and overall well-being of patients living with HIV.

When managing a client on antiretroviral therapy (ART) who develops drug-sensitive tuberculosis (TB), healthcare providers should ensure that the TB treatment and ART are managed in an integrated manner. This means that both treatments should be coordinated and monitored during the same clinical consultation visits to avoid the need for additional visits and reduce the risk of the patient becoming disengaged or lost to follow-up.

The other options provided in the question are not recommended actions for managing a client on ART who develops drug-sensitive TB. Immediately discontinuing ART can have negative consequences for the patient’s HIV management, and starting TB treatment only after completing ART can delay necessary treatment for TB. Referring the patient to a specialized TB treatment center and discontinuing ART management may lead to fragmented care and potential gaps in treatment. Treating TB and HIV independently can also increase the risk of drug interactions and complications for the patient.

In summary, integrating TB management and ART for clients with drug-sensitive TB is the recommended approach to ensure comprehensive and effective care for these individuals.

Neurosyphilis is a complication of syphilis that occurs when the bacterium Treponema pallidum infects the central nervous system. This can lead to a variety of neurological symptoms, including headaches, confusion, memory problems, and even paralysis.

Neurosyphilis most commonly occurs during the tertiary stage of syphilis, which is the most advanced stage of the disease. During this stage, the infection has spread throughout the body and can affect multiple organ systems, including the central nervous system.

It is important to note that neurosyphilis can also occur in earlier stages of syphilis, but it is most commonly seen in the tertiary stage. This is why it is crucial for individuals with syphilis to seek prompt treatment to prevent the progression of the disease to more severe stages, including neurosyphilis.

The guidelines outline the criteria for switching existing clients to DTG-containing regimens for those who have been on PI-based regimens for more than two years. The decision to switch is dependent on the client’s viral load in the last 12 months, and even clients who have failed a previous regimen are considered for switching to a DTG-containing regimen, regardless of their viral load, aiming to optimize their treatment.

Bacterial pneumonia in HIV patients can be more severe and difficult to treat compared to non-HIV patients. Therefore, the preferred antibiotics for managing bacterial pneumonia in HIV patients treated as outpatients are oral beta-lactam plus an oral macrolide. This combination provides broad coverage against common pathogens causing pneumonia, including Streptococcus pneumoniae and Haemophilus influenzae.

IV ceftriaxone alone is not preferred for outpatient treatment as it requires intravenous administration and may not be necessary for mild to moderate cases of bacterial pneumonia. Oral azithromycin alone may not provide adequate coverage for all pathogens causing pneumonia in HIV patients. IV respiratory fluoroquinolone alone is an alternative option but may be reserved for cases where beta-lactam antibiotics are contraindicated or ineffective.

Doxycycline is not typically recommended as the first choice for treating bacterial pneumonia in HIV patients due to concerns about resistance and limited coverage against certain pathogens. Overall, the guidelines recommend oral beta-lactam plus an oral macrolide as the preferred treatment option for outpatient HIV patients with bacterial pneumonia.

Pregnant women who are healthcare workers and are exposed to occupational needlestick injuries are at risk of contracting HIV. In order to prevent HIV transmission to the fetus, post-exposure prophylaxis (PEP) is recommended.

Among the options provided, TLD (tenofovir/lamivudine/dolutegravir) is the preferred antiretroviral medication for PEP during the first trimester of pregnancy. This is because TLD is considered safe and effective for use in pregnant women, with minimal risk of adverse effects on the fetus. Additionally, TLD has a high barrier to resistance and is well-tolerated by most patients.

It is important to follow the recommendations of the National Department of Health (NDOH) or other relevant guidelines when selecting antiretroviral medications for pregnant women in their first trimester who have been exposed to HIV through occupational needlestick injuries. This ensures that the most appropriate and effective treatment is provided to protect both the mother and the developing fetus.

In cases where a mother is known to have chronic hepatitis B and has positive results for both HBsAg and HBeAg, the most appropriate strategy for reducing the vertical transmission rate to the newborn is to give the newborn hepatitis B vaccine along with hepatitis B immunoglobulin. This combination helps provide immediate protection to the newborn against the virus.

The presence of HBeAg indicates that the mother is actively infected and can transmit the virus to others, including her newborn. By giving both the vaccine and immunoglobulin to the newborn, the chances of vertical transmission are significantly reduced.

It is important to follow the guidelines provided in the Green Book, which recommend giving the vaccine and immunoglobulin in cases of active infection. If the mother had antibodies present (anti-Hbe), indicating a non-active infection, then only the vaccine would be given to the newborn.

Overall, the combination of hepatitis B vaccine and immunoglobulin is the most effective strategy for reducing the risk of vertical transmission of hepatitis B from an infected mother to her newborn.

Resistance testing is required for clients failing a DTG-based regimen when their viral load exceeds 1000 c/mL on at least three occasions over two years. This threshold indicates a consistent failure of the current treatment regimen and suggests the presence of drug resistance mutations. Resistance testing helps healthcare providers identify specific mutations that may be causing treatment failure, allowing for the selection of a more effective alternative regimen. By conducting resistance testing in these cases, healthcare providers can optimize treatment outcomes and prevent further development of drug resistance.

Hepatitis B is a viral infection that can be transmitted through exposure to infectious blood or body fluids. Perinatal transmission, which occurs around the time of birth or through contact with infected blood during childhood, is the most common route of transmission worldwide. In areas where hepatitis B is common, the virus is often passed from mother to child during childbirth, with a 20% risk of transmission if the mother is positive for HBsAg. This risk increases to 90% if the mother is also positive for HBeAg. In areas where hepatitis B is rare, intravenous drug use and sexual intercourse are more common routes of transmission. Overall, perinatal transmission is the most common route of hepatitis B transmission globally.